Ocean · Ark2 Labs
Precision bioprospecting in the Ring of Fire.
Ark2 Labs is a joint venture between Digital Aqua and the Odysea Foundation, a scalable platform for natural product discovery, IP monetisation and marine conservation finance.
The thesis
Unlocking the billion-dollar potential of marine microbes.
Bioprospecting, the search for novel compounds in nature, is fuelling the next wave of pharmaceutical and biotech innovation. Drug discovery faces a real-world, contextualised, AI-ready data gap, and coastal marine microbial communities remain the most underexplored source of valuable Biosynthetic Gene Clusters (BGCs).
Ark2 Labs is planning a three-stage, six-year expedition program across the Pacific Ring of Fire, a chain of underwater volcanoes encircling biodiversity hotspots known for extreme environments and rare genetic resources.
Commercial edge
Four advantages no one else can match.
Precision Hotspot Targeting
Our proprietary Marine Asset Prospecting Platform (MAPP) combined with University of Miami NASA satellite sensing (ECOSTRESS, EMIT) maps thermal and optical microclimates at 70 m² resolution, 250× finer than current marine platforms.
Novel BGC Discovery
Metagenomic and metatranscriptomic sequencing pipelines surface uncultured strains, novel Biosynthetic Gene Clusters (BGCs) and metagenome-assembled genomes from coral biofilms, sediments, mangroves and seagrass beds.
AI-Ready Contextual Data
Every BGC is enriched with 20+ environmental parameters and modelled in a Neo4j knowledge graph with agentic AI layers, queries run ~1,000× faster than relational databases.
Blockchain-Secured IP
ClimateChain provides immutable data provenance, frictionless licensing, auditable revenue flows and automated Nagoya-Protocol benefit-sharing.
Research platforms
Three coordinated assets, one global sampling program.
S/Y ODISEA — Coral Triangle
39 m low-emissions expedition sailing vessel with onboard genetics lab. High-resolution mapping, sample collection and sequencing across the world's richest reefs.
Target yield
72,000 BGCs / year
S/Y Cocal — South Pacific
23 m remote expedition vessel with retractable keel for shallow atolls and former nuclear-testing sites, capturing extreme-environment samples and radioactivity data.
Target yield
72,000 BGCs / year
Field Genetics Lab — Baja, Mexico
Shore station in Magdalena Bay where cold and warm currents converge. Local employment, capacity building and new technique development.
Target yield
72,000 BGCs / year
3,600
Prospecting days over 6 years
10,800
Samples collected and sequenced
1.296M
Total BGCs targeted
12,960
Novel BGCs (1% conservative rate)
From sample to market
The BGC-to-IP pathway.
01
Find
Bioprospect microbial hotspots, collect and sequence samples with novel BGC potential.
02
Identify
Bioinformatic analysis (BiG-SLiCE and similar tools) to characterise gene clusters with unknown sequences.
03
Establish Novelty
Verify uniqueness against global databases; tag with environmental and gene-expression fingerprints.
04
Protect
Secure patents for high-value BGC packages; anchor provenance on ClimateChain.
05
License
Release limited information via secure blockchain for due diligence; negotiate upfront, milestone and royalty terms.
06
Monetise
Receive upfront license fees, then milestone payments through clinical trials and royalties on approved drugs.
Market opportunity
A multi-billion-dollar tailwind.
75% of the $50B antibiotic market, 60% of the $300B anticancer market and 25% of the $120B therapeutic-drug market are still derived from natural sources. Marine BGCs offer 2–4× higher novelty than terrestrial strains, and AI models need exactly this kind of defensible, first-in-class training data.
Target licensing partners include AbbVie, Pfizer, Roche, Novartis, Merck, Sanofi, Ginkgo Bioworks and Recursion.
$3T+
Blue economy by 2030
$21B
Marine-derived pharma market by 2030
$13.1B
Marine biotech market by 2030 (8.7% CAGR)
$350B
Annual pharma R&D spend by 2031
Precedent
PharmaMar — proof that marine bioprospecting works.
Spanish marine biotech PharmaMar has built a multi-decade case study for marine natural-product discovery, validating both the science and the commercial model that Ark2 Labs scales globally.
500K+
Marine samples collected
37%
Clinical success rate
$2.5B
Lifetime revenue
3
Approved drugs to market
Revenue model
80% upfront, de-risked from drug-discovery outcomes.
Upfront BGC Licensing
80%Non-contingent payments, base assumption $200,000 per novel BGC, with industry benchmarks ranging $50K–$3.3M depending on class (NPRS, PKS, Toxins, PKS-NPRS hybrids).
Milestones & Royalties
20%$1.5M milestone per compound entering clinical trials, plus 5% royalty on wholesale pharmaceutical sales over a 10+ year period.
Ark2 acts as the gatekeeper for AI-ready contextualised natural-product discovery data. Big Pharma pays for efficient access to nature's R&D — our revenue does not depend on any single blockbuster.
The ARK2 Token
A separate token. A separate balance sheet.
ARK2 is the digital asset instrument of the Ark2 Labs program — completely independent from the WAI water-credit token. The two share no financial elements, no treasury and no token economics.
- Backed by verified marine bioprospecting activity and BGC licensing revenue
- Recorded on ClimateChain with quantum-safe security and Nagoya-Protocol provenance
- Designed for institutional impact investors, ESG mandates and conservation-aligned capital
- No financial relationship with WAI, sales, treasuries and beneficiaries are fully separate
Token mechanics, allocation and minting schedule: see the ARK2 Whitepaper (forthcoming).
ARK2
Marine Bioprospecting Token
Issuer
Ark2 Labs Ltd.
Chain
ClimateChain
Backed by
Licensed BGC IP
Program
6-year expedition
Conservation by design
Bioprospecting doesn't mine nature — it respects it.
By capturing genetic blueprints rather than physical resources, we eliminate the need for repeated extraction. A single non-invasive sample, akin to a biopsy, enables infinite genetic replication via lab synthesis. The legacy outcome is a sustainable path to biodiversity's commercial potential, where conservation is funded by the value it creates.
- Method
- Non-invasive sampling, akin to a biopsy
- Impact
- One-time collection, no return required
- Resource use
- Infinite replication via lab synthesis
- Compliance
- Nagoya Protocol benefit-sharing, on-chain
Partner with Ark2 Labs
Back the next frontier of marine discovery.
Read the full thesis, expedition plan and IP roadmap, or speak directly with the Digital Aqua / Odysea team.